GLB1L encodes a beta-galactosidase enzyme that cleaves beta-linked terminal galactosyl residues from gangliosides, glycoproteins, and glycosaminoglycans, participating in galactose catabolic processes within cellular vacuoles. The gene exhibits region-specific expression patterns, with relatively high expression in the corpus region of the yak epididymis 1, suggesting a role in the specialized luminal environment that facilitates spermatozoan maturation. GLB1L demonstrates gender-specific dysregulation in hidradenitis suppurativa, where it is upregulated in apocrine glands of female patients alongside other androgen-responsive genes, indicating potential involvement in inflammatory skin pathology with hormonal modulation 2. In colorectal cancer, GLB1L was identified as one of eleven genes significantly differentially expressed across CRC stages (p=0.0001), mapping to multiple cellular pathways including nucleosome and DNA packaging complexes, though the clinical significance of this differential expression remains unclear 3. These findings suggest GLB1L functions in tissue-specific enzymatic processes and may have relevance in both reproductive physiology and disease states, though further investigation is needed to fully elucidate its clinical significance in cancer and inflammatory conditions.